Literature DB >> 24658377

Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions.

Werner Kempf1, Dmitry V Kazakov, Christina Mitteldorf.   

Abstract

: Primary cutaneous B-cell lymphomas (PCBCL) are the second most common form of primary cutaneous lymphomas and account for approximately 25%-30% of all primary cutaneous lymphomas. Both forms of low-grade malignant PCBCL, primary cutaneous follicle center lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma of mucosa-associated lymphoid tissue-type (MALT lymphoma) (PCMZL) represent the vast majority of PCBCL and show an indolent slowly progressive course and an excellent prognosis despite a high recurrence rate. Genetic analysis indicates that PCMZL differ from other forms of extranodal MALT lymphomas. The more common class-switched and the non-class-switched form of PCMZL can be distinguished as two distinctive subsets that differ in the cellular composition, IgM expression, and biological behavior with extracutaneous involvement found in the non-class-switched form. Recently, unusual clinical and histological forms of PCMZL and PCFCL manifesting with miliary or agminated lesions have been described that are diagnostically challenging. In contrast to PCMZL and PCFCL, primary cutaneous diffuse large B-cell lymphoma, leg type, and other rare forms of large B-cell lymphomas such as intravascular large B-cell lymphoma have an unfavorable prognosis. There is an emerging group of Epstein-Barr virus (EBV)-driven B-cell lymphoproliferations including posttransplant lymphoproliferative disorders and mucocutaneous ulcer occurring in immunocompromised patients and EBV-associated diffuse large B-cell lymphoma of the elderly arising in the setting of senescence-linked immunodeficiency. This review reports on recent findings expanding the spectrum of clinicopathological features, differential diagnostic aspects, and the pathogenesis of PCBCL and discusses the group of EBV-associated B-cell lymphoproliferations involving the skin.

Entities:  

Mesh:

Year:  2014        PMID: 24658377     DOI: 10.1097/DAD.0b013e318289b20e

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  8 in total

1.  Extranodal Marginal Zone Lymphoma-like Presentations of Angioimmunoblastic T-Cell Lymphoma: A T-Cell Lymphoma Masquerading as a B-Cell Lymphoproliferative Disorder.

Authors:  Benjamin Kaffenberger; Brad Haverkos; Kelly Tyler; Henry K Wong; Pierluigi Porcu; Alejandro Ariel Gru
Journal:  Am J Dermatopathol       Date:  2015-08       Impact factor: 1.533

2.  Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.

Authors:  Shunyou Gong; Genevieve M Crane; Chad M McCall; Wenbin Xiao; Karthik A Ganapathi; Nathan Cuka; Theresa Davies-Hill; Liqiang Xi; Mark Raffeld; Stefania Pittaluga; Amy S Duffield; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2018-10       Impact factor: 6.394

Review 3.  [Cutaneous lymphomas: new entities and rare variants].

Authors:  W Kempf; C Mitteldorf
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

4.  A case of a primary cutaneous diffuse large B-cell lymphoma, leg type.

Authors:  Claudio Marasca; Gabriella Fabbrocini; Eleonora Cinelli; Giuseppina Fontanella; Dario Marasca; Orlando Zagaria
Journal:  Int Wound J       Date:  2019-12-29       Impact factor: 3.315

Review 5.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

Review 6.  [Treatment of indolent cutaneous B‑cell lymphoma].

Authors:  M Wobser
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

Review 7.  Cutaneous primary B-cell lymphomas: from diagnosis to treatment.

Authors:  Margarida Lima
Journal:  An Bras Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.896

8.  A Literature Revision in Primary Cutaneous B-cell Lymphoma.

Authors:  R La Selva; S Alberti Violetti; C Delfino; V Grandi; S Cicchelli; C Tomasini; M T Fierro; E Berti; N Pimpinelli; P Quaglino
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.